Hormone Replacement Therapy Market Size & Share, by Replacement Therapy (Estrogen, Human Growth Hormone, Thyroid, Testosterone Replacement Therapy); Administration Route (Parenteral, Transdermal, Oral); Indication (Cancer, Growth Hormone Deficiency, Menopause, Male Hypothyroidism, Hypothyroidism) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

Request Free Sample Copy

Report ID: 866
Published Date: Feb 09, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Hormone Replacement Therapy Landscape

AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Abbott Laboratories
Novo Nordisk A/S
Genentech, Inc.
Novartis AG
F. Hoffmann-La Roche Ltd
Merck KGaA
Mylan N.V.
Bayer AG
Eli Lilly and Company

Browse Key Market Insights with Data Illustration:

Hormone Replacement Therapy Market Size & Share, Growth Trends 2033

In the News

Orion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).
Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).

Frequently Asked Questions (FAQ)

Higher number of women hitting menopause and growing cases of anxiety disorders is estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2033.

Possibilities of side-effects of the therapy and the requirement for higher initial investment are estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Abbott Laboratories, Novo Nordisk A/S, Genentech, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Merck KGaA, Mylan N.V., Bayer AG, Eli Lilly and Company, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by replacement therapy, administration route, indication, and by region.

The transdermal is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Companies Dominating the Hormone Replacement Therapy Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the hormone replacement therapy market?

What would be the CAGR of hormone replacement therapy market over the forecast period?

What are the challenges affecting the hormone replacement therapy market growth?

Which region will provide more business opportunities for growth of hormone replacement therapy market in future?

Who are the major players dominating the hormone replacement therapy market?

How are the company profiles selected?

What are the segments in the hormone replacement therapy market?

Which segment captures the largest market size in the administration route in the hormone replacement therapy market?